AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26852497
Drug: System of
RxNorm normalized name: KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: System of early diagnosis and non-pharmacological primary prevention including climatotherapeutic and physiotherapeutic methods, personalized dietary therapy, hypoxic-hypercapnic factors, and educational programs.
Trial: 23546935
Drug: Delamanid-containing regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delamanid-containing regimens (treatment group)
Trial: 21722684
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg CHO hepatitis B vaccine
Trial: 21722684
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg CHO hepatitis B vaccine
Trial: 21722684
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 10 μg and 20 μg groups
Trial: 16689009
Drug: Jinghua Weikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinghua Weikang Capsule (JWC), 160 mg 3 times per day, orally before meals for 4 weeks
Trial: 16689009
Drug: famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg twice per day, orally before meals for 4 weeks
Trial: 9056005
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg intravenously (i.v.) every 8 hours (q8h)
Trial: 9056005
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg orally (p.o.) every 8 hours (q8h)
Trial: 9056005
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg orally (p.o.) every 12 hours (q12h)
Trial: 8285777
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg/day/1.73 m2 surface area)
Trial: 2957052
Drug: Provera (100-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provera (100- and 200-mg tablets)
Trial: 2957052
Drug: Farlutal (500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farlutal (500-mg tablets)
Trial: 8628597
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg/d
Trial: 8198020
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg/d
Trial: 12868997
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg/d
Trial: 11044537
Drug: Dalteparin 5000
RxNorm normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5000 IU daily (prophylactic dose)
Trial: 11044537
Drug: Adjusted-weight dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily
Trial: 8227722
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pre‐filter heparin
Trial: 3955779
Drug: Ceftriaxone 2g
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2g daily (1st trial)
Trial: 3955779
Drug: Ceftriaxone 1g
RxNorm normalized name: CEFTRIAXONE 1GM/VIL/LIDOCAINE 1% INJ KIT
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1g once daily (2nd trial)
Trial: 3955779
Drug: Ceftriaxone 2g
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2g single daily (1st trial)
Trial: 30078506
Drug: Individualized adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized adjuvant treatment based on a molecular‐integrated risk profile
Trial: 30078506
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant treatment; vaginal brachytherapy
Trial: 26724694
Drug: Measurement-based antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement-based antidepressant management
Trial: 27032074
Drug: No antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypertensive medication
Trial: 8678389
Drug: 5 monthly
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 monthly injections of 50 micrograms of rgp 120 in MF59
Trial: 6364329
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg metronidazole 2 times daily for 7 days
Trial: 27050869
Drug: Testosterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (100 mg testosterone gel daily for 6 months)
Trial: 27050869
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo gel daily for 6 months)
Trial: 15866088
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg/day)
Trial: 7578653
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion followed by yohimbine 0.4 mg/kg IV
Trial: 7578653
Drug: Yohimbine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 0.4 mg/kg IV alone
Trial: 6782251
Drug: Intravesical thio-tepa
RxNorm normalized name: thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravesical thio-tepa (30 mg or 60 mg) for ablation
Trial: 6782251
Drug: Intravesical thio-tepa
RxNorm normalized name: thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravesical thio-tepa (30 mg or 60 mg) for prophylaxis
Trial: 17426180
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose albendazole
Trial: 11465013
Drug: Fluoxetine (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (an SSRI)
Trial: 9571599
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens orally for 18 days followed by a combined treatment with MPA for 10 days
Trial: 7924783
Drug: Indwelling catheters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling catheters (Insuflon) for insulin injections
Trial: 25738667
Drug: Hepatitis E
RxNorm normalized name: hepatitis E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis E vaccine
Trial: 17418849
Drug: conjugated estrogen+CA
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conjugated estrogen+CA 50 mg
Trial: 17418849
Drug: EE+CA 52
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EE+CA 52 mg
Trial: 17174226
Drug: Palm oil
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palm oil (60 mL, fresh and deep-fried)
Trial: 17483542
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy
Trial: 31421233
Drug: Consistent stimulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent stimulant medication use (n=53, 9%)
Trial: 27583368
Drug: MVA prime,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA prime, sequential gp140 protein boost (M/M/P/P)
Trial: 27583368
Drug: DNA prime,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA prime, concurrent MVA/gp140 boost (D/D/MP/MP)
Trial: 11966736
Drug: IGF-I (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I (10 ng/ml)
Trial: 11966736
Drug: GH (1000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (1000, 5000, or 50000 ng/ml)
Trial: 11966736
Drug: GH (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (200 and 5000 ng/ml) and IGF-I (10 ng/ml) for 24 and 48 h
Trial: 2205455
Drug: L-acetylcarnitine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (500 mg three times a day)
Trial: 31809439
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral progesterone (400 mg twice daily for 3 days, then once daily until surgical abortion)
Trial: 31809439
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 3 days, then once daily until surgical abortion)
Trial: 28347572
Drug: Paracetamol (1g,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1g, six hourly)
Trial: 28347572
Drug: Nefopam (20mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (20mg, six hourly)
Trial: 20803609
Drug: Relaxation response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relaxation response therapy (RRT)
Trial: 17313507
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of malaria and multivitamin supplementation
Trial: 11318884
Drug: Sumatriptan nasal
RxNorm normalized name: SUMAtriptan nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan nasal spray, 20 mg
Trial: 9848497
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein as half of the daily protein intake
Trial: 22999399
Drug: 0.25mg.kg(‐1) of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group A)
Trial: 22999399
Drug: 0.5mg.kg(‐1) of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group B)
Trial: 9343285
Drug: Calcium Supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Supplement
Trial: 7872895
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered 72 hr after the initiation of continuous 5-FU infusion (Group B)
Trial: 3146539
Drug: Enprostil 70
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 70 mcg/d
Trial: 19040645
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine at breakfast
Trial: 19040645
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine at main mealtime
Trial: 15129595
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine premedication (5 micrograms/kg 1 hr before anesthesia)
Trial: 10423465
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy with ciprofloxacin (750 mg twice daily) plus amoxicillin‐clavulanate (625 mg three times daily)
Trial: 10423465
Drug: Intravenous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy with ceftriaxone plus amikacin
Trial: 8523657
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous NaCl 0.9%)
Trial: 26349479
Drug: Local intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local intra-arterial fibrinolysis (LIF) and Conservative standard treatment (CST)
Trial: 19335503
Drug: At-home preparation
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home preparation group (experimental group)
Trial: 15516638
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (14 days of ferrous sulfate and an antimalarial)
Trial: 15516638
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment (three months of ferrous sulfate and three antimalarial treatments)
Trial: 8182625
Drug: Etodolac coadministered
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac coadministered with MTX (10 mg)
Trial: 8182625
Drug: MTX (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (10 mg) without etodolac
Trial: 23622565
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics + oral steroids (Group 2)
Trial: 23622565
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (Group 1)
Trial: 18467719
Drug: Lapatinib 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,250 mg daily (in patients with EGFR-overexpressed tumors)
Trial: 12583871
Drug: buspirone (5HT1A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (5HT1A receptor agonist)
Trial: 8772550
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered at similar intervals as Acipimox)
Trial: 4091874
Drug: Tramadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50 mg capsules, daily dosage limited to 400 mg for 3 weeks)
Trial: 29571962
Drug: Heparin-free TPE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-free TPE
Trial: 29571962
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin TPE
Trial: 12441015
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine, enalapril, hydrochlorothiazide, or both to control systolic blood pressure to <150 mmHg
Trial: 2178396
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily until complete ulcer healing (Group A)
Trial: 2178396
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg until complete relief of pain (Group B)
Trial: 2178396
Drug: Ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine treatment (both groups)
Trial: 29936455
Drug: Oligomeric proanthocyanidin
RxNorm normalized name: grape seed proanthocyanidins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligomeric proanthocyanidin (OPC) 150 mg/day for 8 weeks
Trial: 25260636
Drug: nNOS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nNOS inhibitor (5 mm N-propyl-l-arginine)
Trial: 25260636
Drug: eNOS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eNOS inhibitor (10 mm N(5)-(1-iminoethyl)-l-ornithine dihydrochloride)
Trial: 25260636
Drug: Non-selective NOS
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective NOS inhibitor (20 mm Nω-nitro-l-arginine methyl ester hydrochloride)
Trial: 10589633
Drug: Forearm IVRA
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forearm IVRA (0.4 mL/kg, max 25 mL)
Trial: 10589633
Drug: Conventional IVRA
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IVRA (0.6 mL/kg, max 45 mL)
Trial: 1927586
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of pseudoephedrine four times a day for 3 days
Trial: 1927586
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules four times a day for 3 days
Trial: 6349925
Drug: Three-phasic oral
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-phasic oral contraceptive Trionetta (30/40/30 micrograms ethinyl oestradiol + 50/75/125 micrograms levonorgestrel)
Trial: 27210034
Drug: Single implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single implants placed in healed ridges
Trial: 21157444
Drug: Rifaximin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (1200 mg/day for 8 weeks)
Trial: 15383479
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) or IV unfractionated heparin (UFH) for short-term treatment of DVT.
Trial: 15383479
Drug: Anticoagulants while
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants while awaiting diagnostic tests for patients with high clinical suspicion of DVT.
Trial: 15383479
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with LMWH or UFH for at least 5 days for acute DVT.
Trial: 15383479
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day.
Trial: 15383479
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with VKA for 3 months for first episode of DVT secondary to a transient risk factor.
Trial: 15383479
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with VKA for at least 6 to 12 months for first episode of idiopathic DVT.
Trial: 8866633
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg quinine
Trial: 2106837
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy
Trial: 22748821
Drug: Linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (5 mg)
Trial: 18833113
Drug: Xydifonum administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xydifonum administered via various modes (electrophoretic, peroral, ointment) with heparin and photopheresis using photomatrix LED equipment.
Trial: 6347277
Drug: Tamoxifen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (30 mg daily for 1 year)
Trial: 29722045
Drug: Body Project
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body Project intervention (n = 17) - participants tracked daily diet and activity, attended four weekly group-based sessions
Trial: 29722045
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (n = 15) - directed to track diet and activity level daily
Trial: 26035740
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules and placebo mouth rinse (PLACEBO)
Trial: 21689411
Drug: Donepezil 23
RxNorm normalized name: donepezil 23 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 23 mg/day
Trial: 19570066
Drug: Draw-the-Family Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draw-the-Family Test (DFT) administered to patients with benign anorectal disease
Trial: 19570066
Drug: Draw-the-Family Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draw-the-Family Test (DFT) administered to patients with organic disease
Trial: 19570066
Drug: Draw-the-Family Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draw-the-Family Test (DFT) administered to patients who failed treatment
Trial: 19570066
Drug: Draw-the-Family Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draw-the-Family Test (DFT) administered to healthy control subjects
Trial: 17095947
Drug: Sodium-selenite (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-selenite (1000 microg as a 30-min bolus injection, followed by 14 daily continuous infusions of 1000 microg intravenously)
Trial: 14985680
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (4 g/day, 56% DHA and 28% EPA)
Trial: 31243641
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets/day for 6 months)
Trial: 20203367
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 mg p/o from the preoperative day till the 7th postoperative day)
Trial: 7144761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitamin E treatment)
Trial: 12189059
Drug: Proven effective
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proven effective treatment
Trial: 365795
Drug: Viminol (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viminol (70 mg) combined with chlordiazepoxide (10 mg)
Trial: 365795
Drug: Chlordiazepoxide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (10 mg)
Trial: 30213641
Drug: Non-selective information
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective information (complete/unbiased) and absolute risk formats (e.g., 0.01 per 100)
Trial: 24571621
Drug: Modified assertive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified assertive intervention based on the international assertive community treatment model
Trial: 22207490
Drug: Fentanyl (FE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (FE, 1-2 μg/kg)
Trial: 20100959
Drug: Control empty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control empty vectors plus saline injections